Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisEffect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.Dyslipidemia associated with chronic kidney diseaseTreatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease.Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.Statins, inflammation and kidney disease.Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.Meta-analysis of statins in chronic kidney disease: who benefits?Lipid lowering in renal disease.Different effects of low weight molecular heparin and unfractioned heparin on lipid profile and coagulation at haemodialysis patients.Statin Use and Survival After Acute Kidney Injury.No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study
P2860
Q24194514-6EB728CF-CE06-414D-BB27-09EF80041F5FQ24241472-F4E2D50D-C53A-4182-A9B2-07ACF74FC94EQ33588706-F2F60071-365C-4DFF-B00B-6FF1326B06D0Q34613884-81C9DA1E-FA12-409B-9CFF-782994B00894Q35020237-8E4BA8A3-0E3C-4345-96C9-66F2B33CAD5EQ37517937-1035FA30-B42D-488E-9321-B56E3684340FQ37638675-EAA1FADC-C767-4F9E-9407-6280007C0697Q37883015-0B4C6FF2-A3DB-44CD-B220-10E1734178FDQ38020764-5DA9BB04-BB72-461D-B9EC-3E2C1F718B16Q38400031-279E3539-7B64-4BE7-B541-5C76FFDD616FQ38878462-D59A6CD9-8073-4772-9DA0-36120935C0DBQ41690923-9B80452D-6FD2-4D0B-B4C4-9C30D8E3D6CBQ42280566-CC190338-B16D-4F15-A999-154FC4A15E4FQ47161734-356E9D00-14B3-47B0-8395-A76BA1BEC41BQ57750598-2953CB0A-06E8-404D-B0FD-941CDAF6F279
P2860
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Long-term fluvastatin reduces ...... ic outcomes (a LIPS substudy).
@en
Long-term fluvastatin reduces ...... -year atherosclerotic outcomes
@nl
type
label
Long-term fluvastatin reduces ...... ic outcomes (a LIPS substudy).
@en
Long-term fluvastatin reduces ...... -year atherosclerotic outcomes
@nl
prefLabel
Long-term fluvastatin reduces ...... ic outcomes (a LIPS substudy).
@en
Long-term fluvastatin reduces ...... -year atherosclerotic outcomes
@nl
P2093
P1476
Long-term fluvastatin reduces ...... ic outcomes (a LIPS substudy).
@en
P2093
Chourmouzios A Arampatzis
Dick Goedhart
Francesco Saia
Marco Ciccone
Massimo Arquati
Michele Cortellaro
Nestor F Mercado
Paulo R Soares
Pim de Feyter
Victor Legrand
P304
P356
10.1016/J.AMJCARD.2004.10.008
P407
P577
2005-02-01T00:00:00Z